Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

373.00USD
4:00pm EDT
Change (% chg)

$7.98 (+2.19%)
Prev Close
$365.02
Open
$367.92
Day's High
$374.84
Day's Low
$367.36
Volume
256,456
Avg. Vol
309,270
52-wk High
$452.83
52-wk Low
$325.62

Latest Key Developments (Source: Significant Developments)

UK regulator gives positive opinion on Sanofi/Regeneron's dupilumab product
Tuesday, 14 Mar 2017 04:30am EDT 

Sanofi : Sanofi says UK's Medicines & Healthcare Products Regulatory Agency (MHRA) has granted dupilumab, a product which treats for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). . The decision means that eligible adults with severe atopic dermatitis can access dupilumab before the drug is granted marketing authorisation in the UK, Sanofi adds in statement .Dupilumab is currently under joint development with Regeneron and Sanofi and its safety and efficacy have not been fully evaluated by any regulatory body. The formal EU regulatory application for dupilumab is currently under review by the European Medicines Agency (EMA)..  Full Article

Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions
Tuesday, 7 Mar 2017 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions .Regeneron Pharmaceuticals Inc says effect of praluent on cardiovascular (CV) morbidity and mortality has not yet been determined.  Full Article

Adverum says Regeneron Pharma elects to extend research term of deal
Wednesday, 1 Mar 2017 04:59pm EST 

Adverum Biotechnologies Inc : Adverum Biotechnologies-on Feb 23, Regeneron Pharma notified Adverum Biotechnologies of election to extend research term of collaboration, licensing deal .Adverum Biotechnologies - Regeneron Pharma elected to extend research term of deal for additional three years, through May 1, 2020.  Full Article

Regeneron posts Q4 adj. profit $3.04/shr
Thursday, 9 Feb 2017 06:32am EST 

Regeneron Pharmaceuticals Inc : Regeneron reports fourth quarter and full year 2016 financial and operating results . Regeneron Pharmaceuticals Inc - Q4 2016 eylea global net sales increased 17 pct to $1.35 billion versus Q4 2015 . Regeneron Pharmaceuticals Inc - in Q4 of 2016, global net sales of praluent were $41 million, compared to $7 million in Q4 of 2015 . Says net product sales were $863 million in Q4, compared to $750 million . Regeneron Pharmaceuticals Inc - total revenues increased by 12 pct to $1.227 billion in Q4 of 2016 . Regeneron Pharmaceuticals Inc - sees 2017 Sanofi reimbursement of Regeneron commercialization-related expenses of $400 million - $450 million . Regeneron Pharmaceuticals Inc qtrly non-GAAP net income per share $3.04 . Qtrly GAAP net income per share $2.19 . Q4 earnings per share view $3.03, revenue view $1.30 billion -- Thomson Reuters I/B/E/S . Regeneron Pharmaceuticals Inc - sees single digit percentage growth over 2016 for eylea U.S. net product sales in 2017 . Regeneron Pharmaceuticals Inc - "also studying dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis" . Regeneron - dupixent may have potential to help additional patients with serious allergic diseases, Phase 3 data in adult asthma patients expected later this year . Regeneron Pharmaceuticals Inc - pre-approval inspection for dupixent has been scheduled for Q1 of 2017.  Full Article

Sanofi buys 87,298 shares of Regeneron's common stock on Jan 11
Friday, 13 Jan 2017 04:28pm EST 

:Sanofi reports open market purchase of 87,298 shares of Regeneron Pharmaceuticals Inc's common stock on Jan 11 - SEC filing.  Full Article

Regeneron says Sanofi plant used to fill drugs now deemed acceptable
Monday, 9 Jan 2017 07:26pm EST 

Regeneron Pharmaceuticals Inc : Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable . Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved . Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4 . Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million .Regeneron sees 2017 capital expenditures $375 million to $450 million.  Full Article

Regeneron says Sanofi plant used to fill drugs now deemed acceptable
Monday, 9 Jan 2017 06:49pm EST 

Regeneron Pharmaceuticals Inc : Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable . Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved . Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4 . Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million .Regeneron sees 2017 capital expenditures $375 million to $450 million.  Full Article

Regeneron Pharmaceuticals reports preliminary Q4 U.S. net sales of eylea injection of $858 mln
Monday, 9 Jan 2017 05:32pm EST 

Regeneron Pharmaceuticals Inc - : Preliminary U.S. net sales of eylea injection of $858 million for Q4 2016 .Preliminary global sales of eylea of more than $5 billion for full year 2016 - sec filing.  Full Article

Regeneron entered into termination agreement relating to master terms and conditions for warrants
Friday, 18 Nov 2016 06:26am EST 

Regeneron Pharmaceuticals Inc - : On nov 14, entered into termination agreement relating to master terms and conditions for warrants, dated as of Oct 18, 2011 . Pursuant to Citi termination agreement,Citi warrant agreement has been terminated effective upon payment by co to Citi of amount of $74.9 million .Pursuant to citi termination agreement, remaining number of warrants held by Citi has been reduced to zero- SEC filing.  Full Article

Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting
Wednesday, 16 Nov 2016 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals-In MONARCH study, sarilumab monotherapy showed superiority over adalimumab monotherapy in adults with active rheumatoid arthritis .Press Release - Regeneron and Sanofi present results from phase 3 MONARCH study of investigational sarilumab at American College of Rheumatology Annual Meeting.  Full Article

More From Around the Web

Doctors, patients urge court to reject ban on cholesterol drug sales

A group of doctors and patients are urging a federal appeals court to overturn a lower court order banning sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent after Amgen Inc won a patent lawsuit against them.